Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 633

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 5
Chunk 633
---
, this risk.

Under
the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted
an evaluation of the effectiveness of our internal control over financial reporting, based on criteria established by the Committee of
Sponsoring Organizations of the Treadway Commission (“COSO”) in its 2013 Internal Control-Integrated Framework. Based on
our evaluation, we concluded that our internal control over financial reporting was effective as of December 31, 2024.

As
of December 31, 2024, we are a non-accelerated filer, and our independent registered accounting firm is not required to issue an
attestation report on our internal control over financial reporting.

Item
9B. Other Information.

During
the three months ended December 31, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement”
or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

None.

 62 

PART
III

Item
10. Directors, Executive Officers, and Corporate Governance.

The
information required by this item of this Annual Report will be included under the caption “Directors, Executive Officers, and
Corporate Governance” in our 2025 Proxy Statement, and is incorporated by reference herein.

Item
11. Executive Compensation.

The
information required by this item of this Annual Report will be included under the caption “Executive and Director Compensation”
in our 2025 Proxy Statement, and is incorporated by reference herein.

Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The
information required by this item of this Annual Report will be included in our 2025 Proxy Statement and is incorporated by reference
herein.

Item
13. Certain Relationships and Related Transactions, and Director Independence.

The
information required by this item of this Annual Report will be included under the captions “Certain Relationships and Related
Party Transactions” and “Board of Directors and Corporate Governance – Director Independence” in our 2025 Proxy
Statement and is incorporated by reference herein.

Item
14. Principal Accountant Fees and Services.

The
information required by this item of this Annual Report will be included in our 2025 Proxy Statement and is incorporated by reference
herein.

 63